Merrick I. Ross

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437

N/A

6.5DataRank · unranked

846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Nature(2022)10.1038/s41586-022-05368-8

N/A

0.874DataRank · unranked

339 citations

Michael A. Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos A. Torres‐Cabala +35 more

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Nature(2022)10.1038/s41586-022-04833-8

N/A

0.731DataRank · unranked

130 citations

Michael G. White, Miles C. Andrews, Manoj Chelvanambi, Russell G. Witt, Joseph R. Daniele +60 more

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma

Annals of Oncology(2020)10.1016/j.annonc.2020.07.016

N/A

0.538DataRank · unranked

35 citations

Chandra Mani Adhikari, Serigne Lo, Robert V. Rawson, Rodabe N. Amaria, Alexander M. Menzies +16 more

Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma

OncoImmunology(2025)10.1080/2162402x.2025.2546402

N/A

0.323DataRank · unranked

7 citations

Simin Kiany, Marie‐Andrée Forget, Roland L. Bassett, Michael A. Davies, Adi Diab +15 more

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma

Nature(2023)10.1038/s41586-023-05892-1

N/A

0.165DataRank · unranked

2 citations

Michael A. Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos A. Torres‐Cabala +35 more

Androgen receptor activity promotes resistance to BRAF-targeted melanoma therapy

Research Square(2020)10.21203/rs.3.rs-58480/v1

N/A

0DataRank · unranked

0 citations

Christopher P. Vellano, Michael White, Miles C. Andrews, Joseph R. Daniele, Mark Titus +41 more

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes

Cancers(2021)10.3390/cancers13215301

N/A

0DataRank · unranked

12 citations

Michael G. White, Russell G. Witt, Anik Banerjee, Michael A. Davies, Guangchun Han +18 more

Data from Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

(2023)10.1158/1078-0432.c.6517693.v1

N/A

0DataRank · unranked

0 citations

Gina R. Petroni, Walter C. Olson, Mark E. Smolkin, Merrick I. Ross, Naomi B. Haas +5 more

Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma

Cancers(2023)10.3390/cancers15143630

N/A

0DataRank · unranked

7 citations

Sridevi Addanki, Yi‐Ju Chiang, Salyna Meas, Vanessa N. Sarli, Joshua Upshaw +6 more

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer

Scientific Reports(2021)10.1038/s41598-021-01473-2

N/A

0DataRank · unranked

23 citations

Angela Marx, Diane D. Liu, Yu Shen, Hui Gao, James M. Reuben +9 more